NASDAQ:BOLT

Bolt Biotherapeutics . Stock News

Healthcare > Biotechnology

Buy BOLT

*Your capital is at risk

$4.51

-0.0600 (-1.31%)

At Close: Nov 17, 2025

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

06:26pm, Wednesday, 12'th Nov 2025

Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.72 per share versus the Zacks Consensus Estimate of a loss of $5.07. This compares to a loss of $8 per share a year ago.

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

04:05pm, Wednesday, 12'th Nov 2025

Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

11:01am, Tuesday, 04'th Nov 2025

Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CSE Bulletin: Consolidation - Bolt Metals Corp. (BOLT)

12:58pm, Monday, 20'th Oct 2025

Toronto, Ontario--(Newsfile Corp. - Le 20 octobre/October 2025) - Bolt Metals Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

04:05pm, Wednesday, 01'st Oct 2025

REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, to

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates

06:26pm, Thursday, 14'th Aug 2025

Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.46 per share versus the Zacks Consensus Estimate of a loss of $6.4. This compares to a loss of $11.2 per share a year ago.

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

04:05pm, Thursday, 14'th Aug 2025

REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, to

Squarepoint Ops LLC Buys New Holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)

03:36am, Wednesday, 11'th Jun 2025

Squarepoint Ops LLC purchased a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange C

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates

06:31pm, Monday, 12'th May 2025

Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.28 per share a year ago.

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

04:05pm, Monday, 12'th May 2025

REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, tod

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

04:05pm, Wednesday, 30'th Apr 2025

CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses an

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

01:00pm, Friday, 25'th Apr 2025

BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by